Seven Fleet Capital Management LP Has $309,000 Holdings in Nektar Therapeutics $NKTR

Seven Fleet Capital Management LP trimmed its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 71.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,300 shares of the biopharmaceutical company’s stock after selling 10,700 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Nektar Therapeutics were worth $309,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. BNP Paribas Financial Markets raised its stake in shares of Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares during the last quarter. KBC Group NV bought a new stake in Nektar Therapeutics during the 1st quarter worth approximately $52,000. Deutsche Bank AG increased its holdings in Nektar Therapeutics by 0.8% during the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock valued at $3,837,000 after purchasing an additional 743 shares in the last quarter. Bayforest Capital Ltd increased its holdings in Nektar Therapeutics by 51.3% during the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 862 shares in the last quarter. Finally, State of Wyoming bought a new position in Nektar Therapeutics in the 1st quarter valued at $67,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Insider Buying and Selling

In other Nektar Therapeutics news, CEO Howard W. Robin sold 10,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the sale, the chief executive officer owned 65,045 shares of the company’s stock, valued at approximately $3,923,514.40. The trade was a 13.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Zalevsky sold 5,681 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total transaction of $397,670.00. Following the sale, the insider owned 9,756 shares of the company’s stock, valued at $682,920. The trade was a 36.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 21,862 shares of company stock worth $1,379,205. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics Trading Down 1.1%

Shares of NASDAQ NKTR opened at $70.67 on Friday. The firm has a market capitalization of $2.39 billion, a PE ratio of -8.39 and a beta of 1.13. Nektar Therapeutics has a 1 year low of $21.02 and a 1 year high of $109.00. The firm’s 50-day moving average is $65.66 and its 200-day moving average is $66.44.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The business had revenue of $10.86 million for the quarter, compared to analyst estimates of $10.69 million. Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%. As a group, equities research analysts anticipate that Nektar Therapeutics will post -9.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NKTR shares. Wedbush reduced their price objective on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, May 11th. Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. HC Wainwright lifted their price target on Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a report on Monday, April 20th. Citigroup upped their price target on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Finally, BTIG Research increased their price objective on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $150.00.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.